Patient-derived NExT exhibited high specificity for PDL1+ tumor cells, primarily attributed to the PD1/PDL1 interaction, which boosts intratumor accumulation, selective active targeting, and the therapeutic index and efficiency of chemotherapeutic drugs, as we showed in a PDL1+ PDX model of TNBC. The gene discussed is CD274; the disease is neoplasm.